UNCY
Unicycive Therapeutics, Inc. [UNCY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
UNCY Stock Summary
Top 10 Correlated ETFs
UNCY
Top 10 Correlated Stocks
UNCY
In the News
UNCY Financial details
Company Rating
-
Market Cap
42.4M
Income
-41.19M
Revenue
675K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
14
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.84
Forward P/E
-
PEG
-0.1
P/S
51.49
P/B
9.5
P/C
-
P/FCF
-1.74
Quick Ratio
0.93
Current Ratio
1.2
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.25
EPS next Y
-
EPS next Q
-
EPS this Y
3.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
69.23%
-
-
-
-
SMA20
25%
SMA50
25%
SMA100
-28.57%
Inst Own
-
Inst Trans
-
ROA
-199%
ROE
-763%
ROC
-4.96%
Gross Margin
100%
Oper. Margin
-2931%
Profit Margin
-5737%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.47-1.9
52W High
-
52W Low
-
RSI
55
Rel Volume
1.42
Avg Volume
347.11K
Volume
494.24K
Perf Week
-1.43%
Perf Month
21.72%
Perf Quarter
-14.84%
Perf Half Y
-25.73%
-
-
-
-
Beta
2.648
-
-
Volatility
0.18%, 0.37%
Prev Close
0.42%
Price
4.82
Change
1.15%
Company Profile
- Volume Average 347.11K
- Market Capitalization 42.4M
- Employee 14
- CEO Dr. Shalabh K. Gupta M.D., MPA
- Headquarters Los Altos,CA,US
- IPO Date 2021-07-12
-
Website
https://www.unicycive.com 
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
